This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Knowing where to keep your cash savings securely is essential for peace of mind. Explore the safest options available to you.
22,893 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Vertex’s $10 billion cash bid for Crinetics sparked a sharp rally, lifting the stock nearly to the offer price as tra...
As Veracyte approaches its Q4 2025 earnings, investors want a clear view of revenue momentum, margins, and reimbursem...
With bond yields getting slashed, income-minded investors are turning to dividend stocks that blend steady payouts wi...
This week brought a sharp 19% drop in first majestic silver corporation shares. In this article, we break down the ma...
When Road releases its Q2 results, the transcript hides clues about growth and risk. This guide translates the road 2...
A lump-sum windfall sitting in cash while markets churn often misses the gains of staying invested. Experts say a dis...
As SpaceX eyes an IPO, investors wonder how Starlink's trajectory could change. This guide breaks down potential futu...
Two very different retail giants compete for investors' attention in 2026. This guide breaks down whether Abercrombie...
A fresh AI hardware rally lifts Super Micro Computer while Meta Platforms remains the core beneficiary of AI spend, e...
A sharp look at how Rivian Automotive and Tesla earn money, where their revenue comes from, and what the trends mean ...
Soleno's Q4 2025 earnings paint a picture of growth with new products and expanding margins. This guide breaks down t...